IRIS
BIANCHINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.778
AS - Asia 2.704
NA - Nord America 1.724
SA - Sud America 419
AF - Africa 42
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 7.670
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.738
US - Stati Uniti d'America 1.606
SG - Singapore 1.024
CN - Cina 904
IT - Italia 486
BR - Brasile 344
HK - Hong Kong 320
VN - Vietnam 211
DE - Germania 122
FR - Francia 117
BD - Bangladesh 86
GB - Regno Unito 72
NL - Olanda 68
CA - Canada 66
FI - Finlandia 59
IN - India 45
MX - Messico 36
AR - Argentina 29
PL - Polonia 28
AT - Austria 22
JP - Giappone 19
ZA - Sudafrica 18
SE - Svezia 17
EC - Ecuador 14
ES - Italia 14
CO - Colombia 13
PK - Pakistan 13
ID - Indonesia 12
IQ - Iraq 12
TR - Turchia 11
UA - Ucraina 8
MY - Malesia 7
CR - Costa Rica 6
NP - Nepal 6
PY - Paraguay 6
TN - Tunisia 6
UZ - Uzbekistan 6
LT - Lituania 5
VE - Venezuela 5
KE - Kenya 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
GT - Guatemala 3
HU - Ungheria 3
IE - Irlanda 3
JO - Giordania 3
KR - Corea 3
RO - Romania 3
SA - Arabia Saudita 3
AL - Albania 2
AZ - Azerbaigian 2
GE - Georgia 2
KG - Kirghizistan 2
MD - Moldavia 2
OM - Oman 2
PH - Filippine 2
TW - Taiwan 2
UG - Uganda 2
UY - Uruguay 2
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
MR - Mauritania 1
MT - Malta 1
NI - Nicaragua 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 7.670
Salva come PNG Salva come JPEG
Città #
Singapore 536
Moscow 379
Hong Kong 317
San Jose 270
Ashburn 237
Dallas 182
Shanghai 148
Beijing 113
Hefei 106
Milan 89
Lauterbourg 88
New York 88
Ho Chi Minh City 83
Council Bluffs 61
Los Angeles 53
Hanoi 52
Rome 48
Boardman 46
Nuremberg 39
Santa Clara 39
São Paulo 37
Orem 36
Lappeenranta 25
Warsaw 25
Mexico City 24
Guangzhou 23
Helsinki 23
Montreal 23
Brescia 18
Brooklyn 16
Chicago 16
Munich 16
London 15
Atlanta 14
Cesano Boscone 14
Poplar 14
Shenzhen 14
Phoenix 13
Tokyo 13
Denver 12
Falkenstein 12
Johannesburg 12
Manchester 12
Toronto 12
Chennai 11
Florence 11
Rio de Janeiro 11
Boston 10
Curitiba 10
Bari 9
Buffalo 9
Houston 9
Stockholm 9
Amsterdam 8
Assago 8
Bologna 8
Brasília 8
Calgary 8
Campinas 8
Frankfurt am Main 8
Lahore 8
San Francisco 8
Vienna 8
Belo Horizonte 7
Charlotte 7
Genoa 7
Hangzhou 7
Las Vegas 7
Naples 7
New Delhi 7
Turku 7
Wolfhagen 7
Baghdad 6
Dhaka 6
Jiaxing 6
City of London 5
Comun Nuovo 5
Dublin 5
Hải Dương 5
Jacksonville 5
Lawrence 5
Paris 5
Porto Alegre 5
Princeton 5
Quito 5
Reston 5
Seattle 5
Tashkent 5
Venice 5
Verona 5
Xuzhou 5
Asunción 4
Biên Hòa 4
Da Nang 4
Haiphong 4
Joinville 4
Kuala Lumpur 4
Pisa 4
Pittsburgh 4
Pune 4
Totale 3.779
Salva come PNG Salva come JPEG
Nome #
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 158
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment 148
Spatial predictors of immunotherapy response in triple-negative breast cancer 147
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial 124
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 113
Completion Rate and Positive Results Reporting among Immunotherapy Trials in Breast Cancer, 2004-2023 113
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial 113
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response 112
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 108
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 105
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 104
PARP Inhibitors for Breast Cancer Treatment: A Review 102
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 101
Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer 95
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 95
Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers 92
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 91
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. 91
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 90
Pet/mri for staging the axilla in breast cancer: Current evidence and the rationale for snb vs. pet/mri trials 89
[18F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial 88
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 87
Immunotherapy for early triple negative breast cancer: research agenda for the next decade 87
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 86
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 85
Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. 85
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 84
BREAST CANCER GENOMICS: CHALLENGES IN INTERPRETATION AND APPLICATION 83
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer 82
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 82
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 81
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 81
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial 78
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 77
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. 77
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672] (Cancer Treatment Reviews (2024) 123, (S0305737223001652), (10.1016/j.ctrv.2023.102672)) 75
BIOLOGICAL PROCESSES ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN MOLECULAR SUBTYPES OF BREAST CANCER 74
An unmet need: tailoring extended adjuvant endocrine therapy. 74
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients 73
Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer 73
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer 71
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 71
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 71
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 69
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer 67
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 67
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer 67
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer 64
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers 64
Somatostatin response to a mixed meal in normals and in type I diabetics 63
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions 63
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 62
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial 62
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel 61
Prognostic significance of a signature based on senescence-related genes in colorectal cancer 61
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial 60
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak 60
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized? 60
Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer 60
NEW STRATEGIES IN BREAST CANCER: IMMUNOTHERAPY 59
Immunological differences between primary and metastatic breast cancer 58
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 57
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer 57
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 56
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab 55
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer 54
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease 53
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 53
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. 53
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 53
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. 52
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. 52
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. 52
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. 51
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer 50
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice 49
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies 49
Dissecting time- from tumor-related gene expression variability in bilateral breast cancer 49
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. 48
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer 48
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 48
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. 48
Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients 48
Is trastuzumab as a single agent obsolete in early breast cancer? No 47
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care 46
Molecular heterogeneity of estrogen receptor-positive breast cancer explains variable and contradictory results of randomized adjuvant chemotherapy trials in breast cancer 45
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer 44
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report 44
Introducing new molecular technologies into routine clinical cancer care: Is there an impact on the treatment of breast cancer? 44
DNA REPAIR GENE PATTERNS AS PROGNOSTIC AND PREDICTIVE FACTORS IN MOLECULAR BREAST CANCER SUBTYPES 44
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. 44
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer 44
The immune system and response to HER2-targeted treatment in breast cancer. 43
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 43
Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief 42
Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. 41
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer 41
Treatment options in hormone-refractory metastatic prostate carcinoma. 40
Surrogate markers for targeted therapy-based treatment activity and efficacy. 40
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers 39
Totale 7.009
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.757
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.757
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 0 0 0 0 2 1 1 0 0
2022/202322 11 4 1 0 0 2 0 1 0 0 0 3
2023/2024204 0 0 3 3 1 42 12 8 1 3 60 71
2024/20251.778 239 82 15 96 164 150 287 214 232 96 91 112
2025/20265.983 352 387 271 650 456 206 588 446 1.772 395 223 237
Totale 7.993